Hereditary Testing Market – By Disease Type, By Technology – Global Forecast, 2025 to 2034

Hereditary Testing Market Size

The global hereditary testing market size was valued at USD 7.6 billion in 2024 and is estimated to grow at 7.7% CAGR from 2025 to 2034. Hereditary testing also termed genetic testing is where an individual’s DNA is explored to detect inheritance mutations in their chromosomes, genes, or proteins from their parents.
 

These examinations are conducted to evaluate the chances of an individual getting certain genetic disorders, validate a suspected genetic disease or even determine the chances of offspring getting such disease. The growth of the hereditary testing market is supported by a number of factors. The rising prevalence of genetic disorders combined with increased awareness to their implications has increased hereditary testing needs. For example, the World Health Organization (WHO) estimates that genetic disease and congenital abnormalities are present in 2-5 percent of all live births worldwide. As people get better knowledge on their genes, the demand for taking a health initiative is increasing and the market is expected to grow.

The growth of the market is compounded by a recession in genomic technologies which have made testing inexpensive and easier to get. Strengthening this trend is the integration of hereditary testing into general practice and government policies that foster its use. The use of hereditary testing for purposes other than prenatal diagnosis, such as cancer predisposition, has increased its popularity. The focus on precision medicine, in which individual treatment is prescribed according to the genetic composition of the patient, is also favorable for the market. In addition, the growth of the market is provided by the availability of genetic testing directly to the proposed consumers, which allows them to make their own health decisions.
 

As geneticists and technologists continue to unravel the complexities of genetics, this space is expected to flourish with research looking deeper into genes while also coming up with better research tools.
 

Hereditary Testing Market Trends

• The market for hereditary testing has burgeoned in recent years, due to the awareness about genetic disorders and advancements in genomic technologies. As more and more people are seeking to gain an insight into their predisposition genes, the supply of hereditary testing services in different medical institutions has tended to increase.
   
• Next-generation sequencing (NGS) has greatly enhanced hereditary testing as it is cheaper and more efficient due to it being more comprehensive. As a result of this invention, multi-gene panel tests have been created which improve diagnosis as multiple hereditary conditions can be checked at once.
   
• The market for DTC genetic testing has grown, giving people access to their genetic information, without having to go through qualified personnel. However, this led to discussions regarding how the results should be interpreted, and how genetic counseling should be conducted in order to avoid miscommunications regarding the results of the tests.
   
• The growing demand for precision medicine is also supplementing the hereditary testing markets as these zucits become crucial for devising successful treatment strategies for different diseases, notably oncology. This has led to an increased effort to incorporate genetic testing into normal clinical practice.
   
• The Covid-19 outbreak was partly responsible for the acceptance of remote genetic counselling and other telemedicine services to a wider segment of the population. Moreover, this triggered the creation of home use sample collection kits for genetic testing.
   
• As stated above, the use of artificial intelligence and machine learning is helping in analyzing larger genetic databases and with this, the accuracy and the speed of variant interpretation is improved during hereditary testing. This trend is expected to continue as these technologies become more refined.
   
• Finally, it is recognized that there is a need to broaden the scope of hereditary testing in order to overcome the underrepresentation of some population groups in genetic databases. This will help in enhancing the accuracy of genetic risk prediction for various ethnic groups and optimizing the use of hereditary testing methodologies.
   

Hereditary Testing Market Analysis

Based on disease type, the market is segmented into hereditary cancer testing and hereditary non-cancer testing. The hereditary non-cancer testing segment dominated the market with the largest revenue of USD 5.5 billion in 2024 and is expected to grow at a significant CAGR over the forecast period.
 

• The increase in hereditary non-cancer testing is being driven by the increasing recognition and understanding of genetic disorders and the necessity of timely intervention. This growing knowledge among patients and health care providers has resulted in an increasing uptake in genetic screening and counseling.
   
• Moreover, progress made in genetic testing’s next-generation sequencing instruments is improving the availability and precision of hereditary non-cancer tests. Technological improvements of these sorts are also making testing cheaper and more in reach, which aids further in the growth of the market.
   
• Also, the increase in the prevalence of inheritable conditions as well as the rise in the demand for personalized medicine are also promoting the growth of this segment in the genetic testing market. For example, the World Health Organization (WHO) estimates that almost 5% of the world population is hemoglobin disorder gene carriers, mostly thalassemia and sickle-cell diseases. As the concept of individualized treatment continues to become more prevalent in the medical field, hereditary non-cancer testing is proving to be a useful tool in patient management and disease preventative measures.

Based on technology, the hereditary testing market is segmented into cytogenetic, biochemical, and molecular testing. The molecular testing segment of the market, which held a 54.1% share in 2024, is poised for substantial growth in the coming years.
 

• The emergence of multiplex PCR assays has greatly improved the efficiency of genetic testing. These assays allow testing of many different genetic variants in a single genetic test thus reducing the use of time and money on numerous genetic screenings.
   
• Integration of AI and machine learning algorithms into molecular testing platforms has also enhanced data prediction and variant classification. All these advancement in different technologies allow a clearer picture of the if mutations and variants which are associated with the disease are present or not in the context of genetic testing.
   
• In addition, the growing market for molecular diagnostic technologies in reproductive genetics and the detection of hereditary diseases has been bolstered by the increased use of non-invasive prenatal testing (NIPT) via cell-free DNA analysis.

The U.S. dominated the North American hereditary testing market with revenue of USD 2.2 billion in 2024 and is projected to witness substantial growth over the forecast period.
 

• The widespread prevalence of genetic disorders and cancer cases in the U.S. significantly pushes the market. As per Centers for Disease Control and Prevention (CDC) statistics, hereditary cancer comprises of 5 - 10 percent of cancer cases in the U.S. This considerable spread of knowledge slowly but steadily boosts the market seeking out genetic testing, especially cancer and genetics-afflicted individuals.
   
• With the rapid emergence of genetic testing as a marketable good, the expanding adequacy and reimbursement aspects already set and run by U.S. health insurance providers, are likely to emerge as another force triggering growth in the U.S. market. Recently, large-scale insurers diversified their anti hereditary makeup highly irregular coverage to various population segments. For example, in the U.S., the Centers for Medicare & Medicaid Services (CMS) has increased the coverage for next-generation sequencing tests for patients with progressive cancer and therefore promoting the growth of the market in the U.S.
   

The hereditary testing market in the UK is expected to experience significant growth from 2025 to 2034.
 

• The 100,000 Genomes Project and the NHS Genomic Medicine Service are examples of how the UK government has invested in genomic medicine. Their goal is to make genetic testing a normal part of a medicine. Such initiatives make a contribution towards the development of the market. Not only has the UK’s focus shifted to genomic medicine and awareness on the need for genetic testing increased, but so has the necessary infrastructure and human capital to facilitate such services.
   
• In addition, the rising number of patients with genetic diseases in the UK also brings another market booster. As reported by NHS, 1 in every 25 born children in the UK is born with a genetic disease. The largest incidence in our country has increased the need for more genetic testing services, especially prenatal and newborn screening programs, thus increasing the growth of the market.
   

The Asia Pacific hereditary testing market is anticipated to witness lucrative growth between 2025 and 2034.
 

• The growth of hereditary testing in the Asia Pacific region is accelerating due to the increase in genetic disorders in China and India. Forcing these nations with densely populated countries to seek genetic testing services.
   
• Moreso, there is an increase in understanding in the healthcare sector as well as in the community about the significance of early intervention and the use of genetic data for tailoring better treatment which is also aiding growth of the market in the region.
   
• Also, Japan and South Korea are advancing in healthcare development and technology, which is encouraging progress in the Asia Pacific market. And these countries are building infrastructure with significant investment in genomic research and precision medicine programs that make genetic testing services more advanced and affordable.
   
• Hence, the factors mentioned above will continue to enhance the Asia Pacific market in the ensuing years.
   

The hereditary testing market in Saudi Arabia is expected to experience significant growth from 2025 to 2034.
 

• The growing realization of genetic disorders within the citizens of Saudi Arabia is a crucial factor fueling the market. There is a high rate of intermarriage in the country, increasing the odds of suffering from genetic disorders. Popularization of this cultural aspect and the public health campaigns aimed towards integration of society on genetic risks have given rise to the demand of services for hereditary testing, mostly in the areas of prenatal and premarital screenings.
   
• Another major factor is the considerable funding that the Saudi government provides for health care systems development and genomic research. The Saudi Human Genome Program which was initiated as part of the Saudi Vision 2030 is focused on sequencing 100,000 human genomes in order to search for mutations that are unique to the Saudi population. This endeavor has not only increased the provision of genetic testing services, but it has also increased the efficiency of diagnosis for hereditary diseases and in turn the growth of the market.
   

Hereditary Testing Market Share

With companies such as Myriad Genetics and Illumina dominating the competition, it's safe to say that the market is saturated. The market competition rests on things such as accuracy of tests given, how quickly the test results can be offered and the price range. The market is currently observing a trend in acquisition as larger companies purchase specialized genetic testing firms to grow their arsenal. In order to stay relevant, number of sequencers and bioinformatics tools are key. Moreover, companies are investing funds in foreign countries, chiefly in underdeveloped ones where genetic testing is in the process of being implemented.
 

Adapting to various regulations in different regions is rapidly growing in its relevance to the companies that wish to remain at the top of the market. In addition, marketing strategies such as forging partnerships with health care providers and academic institutions are beneficial to the company’s market visibility. Companies capable of providing efficient cost-per-test along with the altering regulatory environment will likely maintain market competitiveness.
 

Hereditary Testing Market Companies

Some of the eminent market participants operating in the hereditary testing industry include:

• Agilent Technologies
• Centogene
• CooperSurgical
• F. Hoffmann-La Roche
• Fulgent Genetics
• Illumina
• Invitae Corporation
• Laboratory Corporation of America Holdings
• MedGenome
• Myriad Genetics
• Natera
• Quest Diagnostics
• Sophia Genetics
• Thermo Fisher Scientific
• Twist Bioscience
   

USPs for Key Players:

• Agilent Technologies: Offers high-precision genomic analysis solutions, leveraging advanced microarray and sequencing technologies to enhance hereditary disease detection.
   
• F. Hoffmann-La Roche: A leader in next-generation sequencing (NGS) and PCR-based hereditary testing, ensuring high accuracy and reliability in genetic diagnostics.
   
• Myriad Genetics: Pioneers in hereditary cancer testing with proprietary risk assessment tools, delivering personalized insights for early disease detection and prevention.
   

Hereditary Testing Industry News:

• In November 2023, Myriad Genetics, Inc. introduced its new MyRisk Hereditary Cancer Test with RiskScore. This advanced test combines genetic testing for hereditary cancer risk with a polygenic risk score for breast cancer. The integrated approach allows for a more accurate assessment of a patient's overall cancer risk, particularly for individuals of diverse ancestries.
   

The hereditary testing market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Disease Type

• Hereditary cancer testing
  • Lung cancer
  • Breast cancer
  • Colorectal cancer
  • Cervical cancer
  • Ovarian cancer
  • Prostate cancer
  • Stomach/gastric cancer
  • Melanoma
  • Sarcoma
  • Uterine cancer
  • Pancreatic cancer
  • Other hereditary cancers
• Hereditary non-cancer testing
  • Genetic tests
    • Cardiac diseases
    • Rare diseases
    • Other diseases
  • Preimplantation genetic diagnosis & screening
  • Non-invasive prenatal testing (NIPT) & carrier screening tests
  • Newborn genetic screening 

Market, By Technology

• Cytogenetic
• Biochemical
• Molecular testing

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE